microRNA signature and expression of Dicer and Drosha can predict prognosis and delineate risk groups in neuroblastoma.
暂无分享,去创建一个
Chih-Hao Chang | H. Kuo | J. Chen | W. London | M. Diccianni | A. Yu | Ruey-Jen Lin | You-Chin Lin | Yuan-Yan Chen
[1] K. Hagino-Yamagishi,et al. [Oncogene]. , 2019, Gan to kagaku ryoho. Cancer & chemotherapy.
[2] D. Higgins,et al. Widespread Dysregulation of MiRNAs by MYCN Amplification and Chromosomal Imbalances in Neuroblastoma: Association of miRNA Expression with Survival , 2009, PloS one.
[3] Gretchen M. Williams,et al. DICER1 Mutations in Familial Pleuropulmonary Blastoma , 2009, Science.
[4] Jan-Fang Cheng,et al. Dicer, Drosha, and outcomes in patients with ovarian cancer. , 2008, The New England journal of medicine.
[5] A. Donfrancesco,et al. Antagomir-17-5p Abolishes the Growth of Therapy-Resistant Neuroblastoma through p21 and BIM , 2008, PloS one.
[6] C. Creighton,et al. Widespread deregulation of microRNA expression in human prostate cancer , 2008, Oncogene.
[7] C. Croce,et al. Specific microRNAs are downregulated in human thyroid anaplastic carcinomas , 2007, Oncogene.
[8] Trees-Juen Chuang,et al. Human p16γ, a novel transcriptional variant of p16INK4A, coexpresses with p16INK4A in cancer cells and inhibits cell-cycle progression , 2007, Oncogene.
[9] K. Cole,et al. Neuroblastomas have distinct genomic DNA profiles that predict clinical phenotype and regional gene expression , 2007, Genes, chromosomes & cancer.
[10] Leonard D. Goldstein,et al. Global microRNA profiles in cervical squamous cell carcinoma depend on Drosha expression levels , 2007, The Journal of pathology.
[11] E. Wiemer. The role of microRNAs in cancer: no small matter. , 2007, European journal of cancer.
[12] O. Delattre,et al. Chromosomal CGH identifies patients with a higher risk of relapse in neuroblastoma without MYCN amplification , 2007, British Journal of Cancer.
[13] Roland Eils,et al. Classification of neuroblastoma patients by published gene-expression markers reveals a low sensitivity for unfavorable courses of MYCN non-amplified disease. , 2007, Cancer letters.
[14] James W Jacobson,et al. MicroRNA: Potential for Cancer Detection, Diagnosis, and Prognosis. , 2007, Cancer research.
[15] T. Golub,et al. Impaired microRNA processing enhances cellular transformation and tumorigenesis , 2007, Nature Genetics.
[16] Simion I. Chiosea,et al. Overexpression of Dicer in precursor lesions of lung adenocarcinoma. , 2007, Cancer research.
[17] R. Stallings,et al. Differential patterns of microRNA expression in neuroblastoma are correlated with prognosis, differentiation, and apoptosis. , 2007, Cancer research.
[18] Y. Fujii,et al. RNASEN Regulates Cell Proliferation and Affects Survival in Esophageal Cancer Patients , 2006, Clinical Cancer Research.
[19] Patrick Warnat,et al. Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] Rajiv Dhir,et al. Up-regulation of dicer, a component of the MicroRNA machinery, in prostate adenocarcinoma. , 2006, The American journal of pathology.
[21] Joel S Parker,et al. Extensive post-transcriptional regulation of microRNAs and its implications for cancer. , 2006, Genes & development.
[22] W. Gerald,et al. Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number. , 2006, Cancer research.
[23] Tara L. Naylor,et al. microRNAs exhibit high frequency genomic alterations in human cancer. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[24] N. Cheung,et al. The MYCN enigma: significance of MYCN expression in neuroblastoma. , 2006, Cancer research.
[25] T. Sugimoto,et al. Diversity in neuroblastomas and discrimination of the risk to progress. , 2005, Cancer letters.
[26] Yuriy Gusev,et al. Real-time expression profiling of microRNA precursors in human cancer cell lines , 2005, Nucleic acids research.
[27] C. Croce,et al. MicroRNA gene expression deregulation in human breast cancer. , 2005, Cancer research.
[28] V. Kim. MicroRNA biogenesis: coordinated cropping and dicing , 2005, Nature Reviews Molecular Cell Biology.
[29] R. Shiekhattar,et al. MicroRNA biogenesis and cancer. , 2005, Cancer research.
[30] Shuta Tomida,et al. Reduced expression of Dicer associated with poor prognosis in lung cancer patients , 2005, Cancer science.
[31] Yuan Yan Chen,et al. Neural networks and belief logic , 2004, Fourth International Conference on Hybrid Intelligent Systems (HIS'04).
[32] Roland Eils,et al. Prediction of clinical outcome and biological characterization of neuroblastoma by expression profiling , 2004, Oncogene.
[33] G. Brodeur. Neuroblastoma: biological insights into a clinical enigma , 2003, Nature Reviews Cancer.
[34] R. Tibshirani,et al. Diagnosis of multiple cancer types by shrunken centroids of gene expression , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[35] M. Omura-Minamisawa,et al. Frequent deregulation of p16 and the p16/G1 cell cycle‐regulatory pathway in neuroblastoma , 1999, International journal of cancer.
[36] F. Berthold,et al. The international neuroblastoma risk groups (INRG): a preliminary report , 1997 .
[37] H. Varmus,et al. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. , 1984, Science.
[38] Wei‐Chao Chang,et al. Observation of peptide differences between cancer and control in gastric juice , 2008, Proteomics. Clinical applications.
[39] E. Connolly,et al. Chromosome 1p and 11q Deletions and Outcome in Neuroblastoma. , 2006, Neurosurgery.
[40] T. Matise,et al. Loss of heterozygosity for chromosome 14q in neuroblastoma. , 2001, Medical and pediatric oncology.